Dahra Teles: First Speaking Experience at HEMO 2026 on First-Line Multiple Myeloma Treatment
Dahra Teles, Medical Advisor at ODC, shared a post on LinkedIn:
“Participating for the first time as a speaker at HEMO 2026, the largest Hematology congress in Latin America, was a very special milestone in my professional career.
At the invitation of Johnson and Johnson, I had the opportunity to present a class on the treatment of multiple myeloma in the first line, discussing the most recent scientific evidence and the importance of individualizing therapeutic strategies.
Sharing this symposium with great references in Hematology made the experience even more meaningful.
I have followed HEMO since medical residency, when I watched the presentations in the audience.
Being on stage now reinforces how much this trajectory is built with continuous study, exchange of knowledge and commitment to the best care for our patients.”
Stay updated with Hemostasis Today.
-
Nov 10, 2026, 16:28Can the VWF to ADAMTS-13 Ratio Predict Mortality in Sepsis-Induced Coagulopathy? – RPTH Journal
-
Nov 10, 2026, 16:28Ruth Willems: PhD Defence at Maastricht University on Thrombosis and Bleeding in HPB Disease
-
Nov 10, 2026, 16:09Edward Lee Carter: Factor XIa Inhibition Enters Clinical Practice
-
Nov 10, 2026, 16:08Edward C.C. Wong: Deriving Ferritin Cutoffs for Iron Deficiency Using RBC Parameters
-
Nov 10, 2026, 16:07Milad Abdalla: Decoding Hemoglobin Electrophoresis – A Practical Diagnostic Reference
-
Nov 10, 2026, 15:13Wolfgang Miesbach: Nonviral Gene Therapy for Haemophilia A Using Lipid Nanoparticles
-
Nov 10, 2026, 14:55Yazan Abou-Ismail: First FDA-Approved Factor XIa Inhibitor for Stroke Prevention
-
Nov 10, 2026, 14:49Ifeanyichukwu Ifechidere: The Role of Coagulation in Anaesthesia and Surgery
-
Nov 10, 2026, 14:37Salih Ehsan: Common Causes of Microcytic Anemia